We hope you enjoyed the first issue of Retina Today and are ready to dive into the second edition.

In these pages, we look at some clinical trial data results presented at the Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting. Incidentally, the meeting drew a record-breaking attendance of 10,250, according to the organization’s Web site.

Of course, we begin this issue by providing updates regarding the status of some of today’s hot agents, ruboxistaurin, pegaptanib, bevacizumab and ranibizumab.

Michael S. Ip, MD, brings us an article discussing angiographic interpretation of neovascular AMD by different reading centers; and from a group out of the New England Eye Center, some interesting implications with regard to high-speed, ultrahigh resolution OCT.

This issue’s special focus is on three retinal surgery studies that were presented at ARVO. Susanne Binder, MD, and colleagues from Vienna discuss 25-gauge surgery and the move toward further miniaturization of surgical tools.

In the SPR Study, Heinrich Heimann, MD, and colleagues evaluated scleral buckling versus primary vitrectomy in retinal detachment. They recommend primary vitrectomy combined with scleral buckling surgery in retinal detachment for pseudophakic and aphakic patients.

Also in the surgery special focus, Robert E. MacLaren, FRCOphth, FRCS, DPhil, shares with us results from a prospective cohort study that assessed the use of autologous transplantation of retinal pigment epithelium for the management of acute exudative AMD.

As we do in every issue, we present a free CME activity, as well as a listing of current clinical trials in the same subspecialty as the issue’s special focus. Please consider discussing with your eligible patients the possibility of participating in clinical trials.

We encourage you to contact us with any questions, concerns or article ideas. Look for our staff at the next scientific meeting and introduce yourself! We want to hear from our readers.